TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Chronic AD, according to American Academy of Dermatology Consensus Criteria (Eichenfield, 2014), that has been present for at least 3 years before the screening visit~2. Eczema Area and Severity Index (EASI) score ≥16 at the screening and baseline visits~3. ≥10% Body surface area (BSA) of AD involvement at the screening and baseline visits~4. Documented recent history (within 6 months before the screening visit) of inadequate response to topical AD medication(s) or for whom topical treatments are medically inadvisable~Key Exclusion Criteria:~1. Prior participation in an anti-Interleukin (IL)-33 class antibody (including but not limited to REGN3500) or anti-IL-4Rα class antibody (including but not limited to dupilumab) clinical study; past treatment with or current treatment with dupilumab or another anti-IL-4Rα treatment~2. Active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals 2 weeks before the baseline visit, or superficial skin infections within 1 week before the baseline visit~3. Known or suspected history of immunosuppression, including history of invasive opportunistic infections (eg, tuberculosis (TB), histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis) despite infection resolution: or unusually frequent, recurrent, or prolonged infections, per investigator judgment~4. History of human immunodeficiency virus (HIV) infection or positive HIV serology at screening~5. Positive with hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), or hepatitis C virus antibody (HCV Ab) at the screening visit~6. Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study~Note: Other protocol defined Inclusion/Exclusion Criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- REGN3500 (Type: EXPERIMENTAL): None
- Dupilumab (Type: EXPERIMENTAL): None
- Combo (Type: EXPERIMENTAL): None
- Placebo (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Plasmalyte Versus Saline in Trauma Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Severe trauma defined by at least one Vittel criteria~* Prescription for at least one red blood cell unit transfusion within 6 hours after trauma~* Delay between trauma and study randomization ≤ 6 hours~* Patient able to give consent or included in emergency situation~* Patient affiliated to Health security system~Exclusion Criteria:~* Age \< 18 years~* Chronic kidney disease needing requiring renal replacement therapy~* Participation to another interventional trial interacting with renal function or which requires the use of a fluid resuscitation~* Fluid resuscitation \> 4000 mL before inclusion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Plasmalyte Viaflo (Type: EXPERIMENTAL): Intervention type: drug (Plasmalyte Viaflo) Intervention name: plasmalyte Intervention description: fluid resuscitation using exclusively Plasmalyte up to 20L during the first 5 days
- NaCl 0.9% (Type: ACTIVE_COMPARATOR): Intervention type: drug (NaCl 0.9%) Intervention name: NaCl 0.9% Intervention description: fluid resuscitation using exclusively NaCl 0.9% up to 20L during the first 5 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: FACBC Positron Emission Tomography/Computed Tomography(PET/CT) Used in the Diagnosis of Primary Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must be 18 years of age or older.~* Patients will be scheduled for prostatectomy based on a diagnosis of primary prostate cancer.~* Ability to lie still for PET scanning~* Patients must be able to provide written informed consent.~Exclusion Criteria:~* Age less than 18~* Inability to lie still for PET scanning~* Cannot provide written informed consent.~* Less than 4 weeks since any prior prostate biopsy (to decrease false positive uptake from inflammation).

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FACBC Imaging (Type: EXPERIMENTAL): Dynamic FACBC PET of primary prostate carcinoma.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: The Stroke Warning Information and Faster Treatment Study (SWIFT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with cerebral infarction/TIA hospitalized at New York Presbyterian Hospital (Milstein Hospital and Allen Pavilion)~* 18 year-old and older at onset of the stroke~* Self-identified as of White, Black or Hispanic race-ethnicity~* Living in a household with a telephone~Exclusion Criteria:~* Patients unable to give informed consent~* Discharged to nursing home or requiring 24 hour care.~* A Modified Rankin score \> 4 at baseline~* Severe aphasia or severe cognitive impairment limiting comprehension~* Pre-stroke dementia history~* Patients with end stage cancer, or other medical conditions resulting in mortality \</= 1 year

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): interactive educational program
- 2 (Type: ACTIVE_COMPARATOR): usual medical care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: ThoHSpEkt Thoracoscopic Ectomy of Radioactively Marked Pulmonary Nodules With Free-hand SPECT

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age over 18 years~* Planed thoracoscopic surgery of a pulmonary nodule~* Informed consent~Exclusion Criteria:~* mental incapacity~* contraindications for this treatment~* pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CT guided labelling (Type: EXPERIMENTAL): CT guided radioactive labelling of pulmonary nodules followed by handheld-SPECT guided thoracoscopic surgery.
- Electromagnetic bronchoscopic labelling (Type: EXPERIMENTAL): Electromagnetic guided bronchoscopic labeling of pulmonary nodules followed by handheld-SPECT guided thoracoscopic surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN® (Brimonidine 0.2%/Timolol 0.5% Fixed Combination) Therapy in Brazil

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older.~* Clinical diagnosis of ocular hypertension, exfoliative open-angle glaucoma, or pigment dispersion glaucoma in at least one eye (study eye).~* Be on a stable intraocular pressure (IOP) lowering regimen within 30 days of the Screening Visit.~* IOP considered safe in both eyes in such a way that should assure clinical stability of vision and optic nerve throughout the study period.~* Best corrected visual acuity of 6/60 (20/200 Snellen; 1.0 LogMAR) or better in each eye.~* IOP between 19 and 35 mmHg in at least one eye (which would be the study eye) while on brimonidine/timolol fixed combination therapy.~* Other protocol-defined inclusion criteria may apply.~Exclusion Criteria:~* Presence of other primary or secondary glaucoma not listed in inclusion criteria #2.~* History of ocular herpes simplex.~* Abnormality preventing reliable applanation tonometry.~* Corneal dystrophies.~* Concurrent infectious/noninfectious conjunctivitis, keratitis, or uveitis in either eye. Blepharitis or non-clinically significant conjunctival injection is allowed.~* Intraocular conventional surgery or laser surgery in study eye(s) less than three months prior to the Screening Visit.~* Risk of visual field or visual acuity worsening as a consequence of participation in the study, in the investigator's best judgment.~* Progressive retinal or optic nerve disease from any cause.~* Use of systemic medications known to affect IOP which have not been on a stable course for 7 days prior to the Screening Visit or an anticipated change in the dosage during the course of the study.~* Pregnant or lactating.~* Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AZARGA (Type: EXPERIMENTAL): Brinzolamide/timolol maleate fixed combination, one drop self-administered in study eye(s) twice a day for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Erythropoietin Role in Acute Kidney Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All adult patients \> 18 years old hospitalized with acute kidney injury and anemia~Exclusion Criteria:~* pregnant women, terminally ill patients, patients with major or minor thalassemia, patients with stable chronic kidney disease or patients on dialysis and patients who were receiving rHuEPO or any erythropoiesis-stimulating agent (ESA) before admission.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Recombinant human erythropoietin 4000 UI will be administered subcutaneously every other day
- Group 2 (Type: NO_INTERVENTION): No recombinant human erythropoietin will be administered to this group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Contingency Management for Smoking Cessation Among Veterans With Psychotic Disorders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All subjects must be diagnosed with schizophrenia or any other psychotic disorder, bipolar disorder with psychotic features, or major depression with psychotic features according to the electronic medical record.~* Current nicotine use, defined as smoking 5 or more cigarettes/day for at least 16 of the past 30 days prior to study screening.~* Prospective subjects must indicate willingness to attend smoking cessation group therapy.~Exclusion Criteria:~* Imminent risk for suicide or violence.~* Severe psychiatric symptoms or psychosocial instability likely to prevent participation in the study protocol (i.e., attendance at scheduled sessions, ability to read study materials, and/or ability to comprehend interventions).~* Clinically apparent, gross cognitive impairment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Experimental
- Arm 2 (Type: ACTIVE_COMPARATOR): Active Comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Role of Obstructive Sleep Apnea in Children With Fatty Liver Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Sleep Apnea as diagnosed by clinical sleep study (Apnea Hypopnea index greater than 1)~* Evidence of NAFLD as diagnosed by screening MRI (hepatic fat fraction ≥5.5%) Obese child/adolescent between 9-21 years old~* Compliance with using C-pap as instructed~Exclusion Criteria:~* Medications or know disease known to alter glucose or insulin metabolism such as oral steroids, or certain psychiatric medications, such as Xeleca, Lithium and Paxil.~* Type 2 Diabetes Mellitus~* Medications for chronic anti-inflammatory effects~* Consumption of alcohol

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- C-PAP intervention (Type: EXPERIMENTAL): Continuous positive airway pressure is a commonly prescribed therapy for obstructive sleep apnea which is recommended for the treatment of obstructive sleep apnea in children and adults.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Lung Structure-Function In SurVivors of Mild and SEvere COVID-19 Infection: 129Xe MRI

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Consent provided~* Aged 12-70 years old~* Meets MRI screening criteria~* Diagnosed with COVID19, documented by positive COVID19 test (Nasopharyngeal swab or saliva swab) and are within 3 months post recovery\*.~  * Recovery from COVID19 is defined as asymptomatic for at least 2 weeks prior to study visit 1 and screen negative based on SickKids guidelines.~Exclusion Criteria:~* Pregnant or lactating\*~* A cold or flu within the last 2 weeks

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Single arm (Type: None): Those participants who have experienced a documented case (documented by positive COVID19 test and/or clinical history) mild or severe COVID19 infection including those with symptoms and those who were hospitalized with COVID19 infection, all of whom are within 3 months post recovery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Vertebral Osteosynthesis in Degenerative Lumbar Stenosis With Spondylolisthesis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with degenerative spondylolisthesis L4-L5 confirmed by radiography with radicular pain for whom the antalgic and anti-inflammatory treatment are not efficient for at least 3 months;~* Patients who agree to take part in the study and to sign an Informed Consent Form~Exclusion Criteria:~* Contre-indications to surgery or to vertebral isolated fixation L4-L5~* Previous lumbar surgery~* Work accidents~* Psychiatric troubles that may interfere with the clinical evaluation~* Pregnant women or women who could be pregnant during the study~* Patient under special supervision or trusteeship~* Refusal to sign the Informed Consent Form~* No Public Health Insurance cover

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): osteosynthesis
- 2 (Type: ACTIVE_COMPARATOR): Simple surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Parkinson's Disease Genetics Database

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have a diagnosis of Parkinson's Disease as determined by standard neurological criteria.~* Patients ≥18 years of age who are able to provide informed consent~* Patients ≥ 18 who are decisionally impaired for whom informed consent can be obtained by a legally authorized representative.~Exclusion Criteria:~* Patients without a diagnosis of Parkinson's Disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Does Vitamin D Improve Glycemic Control in Type II DM?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Type II diabetics living in Riyadh area who consume no more than one serving of milk/day~* Do not take vitamin supplement~* Habitually have less than 10 hour of sun exposure per week~* Don't suffer from granulomatous conditions, liver disease, or kidney disease~* Don't take anticonvulsants, barbiturates, or steroids.~* Stable glycemic control (not more than 0.5% difference between current HA1c and a HA1c obtained 2-4 months earlier)~* Current HA1c between 6.5 and 8%, and current total 25 OH vitamin D level between 10-30 nmol/L.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- vitamin D3 2000 IU (Type: EXPERIMENTAL): None
- vitamin D3 5000 IU (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Surgical Approach to the Management of Type II Diabetes Mellitus in Patients With a BMI Between 25-35 kg/m2

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age- 21-55 years.~* Body Mass Index between 25-35 kf/m2.~* currently being treated for type 2 diabetes mellitus with oral hypoglycemic, insulin or both for the at least 3 years.~* Documented HbA1c\>7.5% for at least 3 months.~* Stable weight for 3 months (+/-)~* Evidence of stable medical treatment for diabetes over the past 12 months.~* Able to provide informed consent -Female subject agrees to participate in accepted birth control methods -~Exclusion Criteria:~* Type I diabetes/juvenile onset~* C-Peptid levels below 1.0 ng/ml~* Previous major upper abdominal surgery~  --Pregnant or plans to become pregnant with in the next 12 months~* Current Malignancy~* Severe pulmonary, cardia, or renal disease~* Eating disorders such as bulimia or binge-eating~* Severe mental health disorders such as schizophrenia and bipolar disorder~* Obesity due to other metabolic disorders~* taking appetite suppressants~* currently abusing illicit drugs,alcohol or using tobacco products~* Unable to provide informed consent~* Unwillingness or unable to comply with study procedures~* any condition that deems them unsuitable for the study in the opinion of the investigators

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Surgical treatment (Type: OTHER): Surgical treatment of one arm of the patient population.
- Medically controlled group (Type: OTHER): Managed by endocrinologists using current medical therapy such as pills, injections and life style medication.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of Valacyclovir Oral Solution in Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is in the age of 2-12 years.~* Subject has an indication for (val)acyclovir prophylaxis and are planned to receive valacyclovir oral solution.~* Subject is managed with a central venous catheter (CVC/Port-a-Cath).~* Subject's parents have signed the Informed Consent Form prior to screening evaluations.~* Subject is willing to participate after study procedures are explained in comprehensible language for the child.~Exclusion Criteria:~* Severe anemia (\<6.0 mmol/L).~* Full dose has not been taken.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Valacyclovir oral solution (Type: OTHER): Valacyclovir oral solution as administered in standard of care. Dosage: 10 mg/kg BID for children weighing less than 40 kg and 500 mg BID for children weighing 40 kg or more.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy